Neptune Technologies & Bioressources Inc. Reports Completion of Acasti Pharma Comparative Benchmarking Program Versus Lovaza(

LAVAL, Quebec, Nov. 25, 2010 (GLOBE NEWSWIRE) — Neptune Technologies & Bioressources Inc. (“Neptune”) (Nasdaq:NEPT) (TSX-V:NTB) subsidiary, Acasti Pharma Inc. (“Acasti”), reports the completion of its preclinical program designed to compare the lipid management effects of Acasti’s drug candidate CaPre™ versus prescription drug Lovaza®.�Blood lipids were monitored in two animal models in order to assess [...] http://bit.ly/dLHDPz